Obeticholic Acid Study [Design Issues]

posted by Researcher101 – Egypt, 2021-02-23 20:35 (214 d 10:22 ago) – Posting: # 22223
Views: 550

Dear All, I'm about to conduct BE study on Obeticholic Acid, I'm a bit afraid from the enterohepatic circulation on OCA and its effect on AUC variability of elimination phase so I'm going for 4 periods fully replicate design to be more conservative,

my question is what are the measures should I take to ensure covering this elimination variability? Is scaling of AUC accepted by FDA or EMA or only scaling Cmax is accepted?
Should I measure AUC0-24 and AUC0-72 or AUC0-72 only and on which the confidence interval will be based? Please Advise

Edit: Category changed; see also this post #1[Helmut]

Complete thread:

 Admin contact
21,700 posts in 4,538 threads, 1,542 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Sunday 07:57 CEST (Europe/Vienna)

A central lesson of science is that to understand complex issues
(or even simple ones), we must try to free our minds of dogma and
to guarantee the freedom to publish, to contradict, and to experiment.
Arguments from authority are unacceptable.    Carl Sagan

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz